Independent minds. Global perspective. A publication for the builders
Biotechnology / Boston

Elliot Tague.

Co-founder
SynsoryBio

Elliot Tague co-founded SynsoryBio, which develops protein therapeutics with conditional sensing functions. The public biography describes synthetic-biology and protein-engineering research and work in biotechnology startups. The company's platform investigates molecules that activate in response to selected biological signals, with proposed applications in cancer and autoimmune disease.

Public-source researchLast checked 1 source ↘
THE STORY, IN CONTEXT

Elliot Tague and the story of SynsoryBio.

SynsoryBio's launch uses conditional logic as the organizing idea for its medicines: a molecule would respond when it encounters a specified marker rather than remain equally active everywhere. The team applies this research to therapeutic candidates whose useful activity may be limited by toxicity. The supplied account establishes that engineering thesis without independently confirming tissue specificity, a wider therapeutic window, safety, or effectiveness in human treatment.

FROM THE PUBLIC RECORD

Public advice & further reading.

No personal advice is attributed in this profile: a verifiable public advice source has not yet been established. The company and activity facts above remain separately sourced.

Suggest a first-person interview or essay ↗
EVIDENCE IN PLAIN SIGHT

Sources & attribution.

  1. 01
    SynsoryBio — Y Combinator company and active founder profile

    Public active-founder biography, current company status and description, and founding-team launch accounts. Company or team statements are attributed accounts, not independently audited performance results.

    www.ycombinator.com
About this profile

Independently researched from the public sources above. Featured people and companies are not affiliated with BusinessBlogz. Source dates and attribution provide context for the information shown; business claims remain attributed to their original source. Role and company details can change after review. The initials graphic is editorial artwork, not a photograph.

Request a correction or update ↗
KEEP EXPLORING

More builders in Biotechnology.

Explore the sector ↗